HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Developmental pharmacology and therapeutics of piperacillin in gram-negative infections.

Abstract
Twenty children ranging in age from 1 week to 19 years with documented or suspected bacterial infections arising outside the central nervous system were studied. Pharmacokinetic analysis was possible in 15 children; 8 after the first dose, 6 during steady-state conditions, and 4 on both occasions. Data were obtained utilizing noncompartmental pharmacokinetic methods. Peak piperacillin serum concentrations ranged from 51 to 232 mg/l and correlated directly (r = 0.75) with the dose administered. In children with normal renal function, there was an age-dependent decrease in elimination half-life and apparent steady-state volume of distribution, whereas plasma clearance increased logarithmically. All but 1 child responded favorably to piperacillin therapy, and 1 child with a urinary tract infection relapsed 10 days after discontinuation of the therapy. Although improved clinically, piperacillin monotherapy failed to eradicate pathogens in 2 children. No adverse clinical or biochemical effects were observed in any child.
AuthorsM D Reed, C M Myers, T S Yamashita, J L Blumer
JournalDevelopmental pharmacology and therapeutics (Dev Pharmacol Ther) Vol. 9 Issue 2 Pg. 102-14 ( 1986) ISSN: 0379-8305 [Print] SWITZERLAND
PMID3956344 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Piperacillin
Topics
  • Adolescent
  • Adult
  • Aging
  • Bacterial Infections (drug therapy, microbiology)
  • Child
  • Child, Preschool
  • Female
  • Gram-Negative Bacteria (drug effects)
  • Humans
  • Infant
  • Kinetics
  • Male
  • Models, Biological
  • Piperacillin (pharmacology, therapeutic use, urine)
  • Urinary Tract Infections (drug therapy, microbiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Research Interface PRO additionally includes drill-down to evidence, articles by author, export to Excel, FDA Link and mobile subscription:
1 year subscription, $490.00 USD